Montelair 10 Mg Film-Coated Tablets (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition reduces airway narrowing, mucus production, and inflammation, helping to control asthma symptoms and allergic nasal reactions.

The dose of Montelair is individualized by the prescriber based on the patient’s age, condition, and response. In many regions adults receive a 10 mg tablet once daily, but the exact regimen should be confirmed with the treating clinician.

Safety data for montelukast in pregnancy are limited and the pregnancy category is listed as unknown. It should be used only if the potential benefit outweighs the risk. Caution is also advised while breastfeeding; consult a healthcare provider for personalized guidance.

To order Montelair, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelair belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients who prefer a once‑daily tablet or need additional control for exercise‑induced symptoms, but it is not a rescue medication for acute attacks.

Montelair tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children.

Montelair is taken orally as a film‑coated tablet. Swallow the tablet whole with a glass of water; it may be taken with or without food. Follow the prescribing clinician’s instructions regarding timing and any dietary considerations.

Serious but rare risks include severe allergic reactions such as rash, angioedema, or anaphylaxis; neuropsychiatric events like depression, mood changes, or suicidal thoughts; and liver enzyme elevations. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelair should not be used by individuals with known hypersensitivity to montelukast or any tablet excipients. It is also unsuitable for treating acute asthma attacks and should be avoided in patients where the prescriber determines the risks outweigh the benefits, such as uncontrolled severe hepatic impairment.